Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Reduce -10.53%0.35%$53.41 - $62.07 $ 59.134%24,339,344
Dodge & Cox 2018-03-31 Reduce -0.04%$53.41 - $62.07 $ 59.134%13,788,353
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -10.06%0.12%$53.41 - $62.07 $ 59.134%12,777,977
Ken Fisher 2018-03-31 Add 4.08%0.02%$53.41 - $62.07 $ 59.134%7,648,258
Richard Pzena 2018-03-31 Add 175.79%0.8%$53.41 - $62.07 $ 59.134%4,524,430
T Rowe Price Equity Income Fund 2018-03-31 Reduce -2.12%0.02%$53.41 - $62.07 $ 59.134%3,690,000
Charles Brandes 2018-03-31 Add 7.69%0.15%$53.41 - $62.07 $ 59.134%1,768,152
Kahn Brothers 2018-03-31 Reduce -1.61%0.13%$53.41 - $62.07 $ 59.134%904,387
Joel Greenblatt 2018-03-31 Add 3.65%0.02%$53.41 - $62.07 $ 59.134%742,473
Robert Bruce 2018-03-31 Add 38.55%1.23%$53.41 - $62.07 $ 59.134%359,400
Mario Gabelli 2018-03-31 Add 0.05%$53.41 - $62.07 $ 59.134%107,759
First Eagle Investment 2018-03-31 Sold Out $53.41 - $62.07 $ 59.134%0
Vanguard Health Care Fund 2017-12-31 Reduce -6.86%0.28%$54.1 - $64.6 $ 59.132%27,204,344
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -6.05%0.09%$54.1 - $64.6 $ 59.132%14,207,029
Dodge & Cox 2017-12-31 Add 2.46%0.01%$54.1 - $64.6 $ 59.132%13,793,936
Ken Fisher 2017-12-31 Add 0.77%$54.1 - $64.6 $ 59.132%7,348,172
T Rowe Price Equity Income Fund 2017-12-31 Add 18.14%0.15%$54.1 - $64.6 $ 59.132%3,770,000
Charles Brandes 2017-12-31 Add 2.70%0.05%$54.1 - $64.6 $ 59.132%1,641,916
Richard Pzena 2017-12-31 Add 7.93%0.03%$54.1 - $64.6 $ 59.132%1,640,524
Kahn Brothers 2017-12-31 Add 0.05%$54.1 - $64.6 $ 59.132%919,209
Joel Greenblatt 2017-12-31 Add 364.18%0.46%$54.1 - $64.6 $ 59.132%716,308
Mario Gabelli 2017-12-31 Add 5.69%$54.1 - $64.6 $ 59.132%107,702
First Eagle Investment 2017-12-31 Add 21.59%$54.1 - $64.6 $ 59.132%33,790
George Soros 2017-12-31 Sold Out 0.01%$54.1 - $64.6 $ 59.132%0
Tweedy Browne 2017-12-31 Sold Out 0.01%$54.1 - $64.6 $ 59.132%0
Vanguard Health Care Fund 2017-09-30 Reduce -2.86%0.12%$61.49 - $66.16 $ 59.13-7%29,209,044
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -2.70%0.04%$61.49 - $66.16 $ 59.13-7%15,122,702
Dodge & Cox 2017-09-30 Reduce -0.70%0.01%$61.49 - $66.16 $ 59.13-7%13,462,469
Ken Fisher 2017-09-30 Add 2.70%0.02%$61.49 - $66.16 $ 59.13-7%7,292,315
T Rowe Price Equity Income Fund 2017-09-30 Reduce -5.33%0.05%$61.49 - $66.16 $ 59.13-7%3,191,200
Charles Brandes 2017-09-30 Reduce -27.00%0.6%$61.49 - $66.16 $ 59.13-7%1,598,786
Richard Pzena 2017-09-30 Add 84.25%0.23%$61.49 - $66.16 $ 59.13-7%1,519,959
Kahn Brothers 2017-09-30 Reduce -1.51%0.14%$61.49 - $66.16 $ 59.13-7%918,730
Joel Greenblatt 2017-09-30 Add 28.10%0.03%$61.49 - $66.16 $ 59.13-7%154,317
Mario Gabelli 2017-09-30 Reduce -3.69%$61.49 - $66.16 $ 59.13-7%101,905
First Eagle Investment 2017-09-30 Add 256.74%$61.49 - $66.16 $ 59.13-7%27,790
George Soros 2017-09-30 New Buy0.01%$61.49 - $66.16 $ 59.13-7%3,500
Vanguard Health Care Fund 2017-06-30 Reduce -6.83%0.31%$61.89 - $66.16 $ 59.13-7%30,067,944
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -1.72%0.03%$61.89 - $66.16 $ 59.13-7%15,542,519
Dodge & Cox 2017-06-30 Reduce -0.96%0.01%$61.89 - $66.16 $ 59.13-7%13,557,699
Ken Fisher 2017-06-30 Add 3.46%0.02%$61.89 - $66.16 $ 59.13-7%7,100,308
T Rowe Price Equity Income Fund 2017-06-30 Reduce -0.13%$61.89 - $66.16 $ 59.13-7%3,370,700
Charles Brandes 2017-06-30 Reduce -15.97%0.39%$61.89 - $66.16 $ 59.13-7%2,190,048
Kahn Brothers 2017-06-30 Reduce -0.77%0.08%$61.89 - $66.16 $ 59.13-7%932,840
Richard Pzena 2017-06-30 Reduce -0.16%$61.89 - $66.16 $ 59.13-7%824,940
Joel Greenblatt 2017-06-30 Reduce -84.30%0.52%$61.89 - $66.16 $ 59.13-7%120,462
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, XSWX:NOVN, XSWX:ROG, XTER:BAYN, LSE:GSK, NYSE:PFE, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422 » details
Traded in other countries:MRK.Argentina, MRK.Austria, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Headquarter Location:USA
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. From a geographical perspective, close to half of the company's sales are generated in the United States.

Guru Investment Theses on Merck & Co Inc

Jeff Auxier Comments on Merck & Co. - Feb 06, 2018

Merck & Co. (NYSE:MRK) had a challenging quarter as total sales declined 2% due to a temporary production shutdown from a cyber-attack. Merck’s Pharmaceutical segment–making up 89% of sales–fell 3% as they lost market exclusivity for two of their top cholesterol treatments and are facing increasing pricing pressure on their top-selling drug. On a positive note, the outlook for cancer-fighting immunotherapy Keytruda is very encouraging.



From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Merck & Co Inc

Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
US Market Indexes Close Higher on Wednesday Dow Jones closes at 24,886.81
U.S. market indexes were higher Wednesday. The Dow Jones Industrial Average closed at 24,886.81 for a gain of 52.40 points or 0.21%. The S&P 500 closed at 2,733.29 for a gain of 8.85 points or 0.32%. The Nasdaq Composite closed at 7,425.96 for a gain of 47.50 points or 0.64%. The VIX Volatility Index closed at 12.58 for a loss of -0.64 points or -4.84%. Read more...
US Market Indexes Close Lower on Thursday Russell 2000 reports another record close while large caps end mostly lower
U.S. market indexes were mostly lower Thursday. The Dow Jones Industrial Average closed at 24,713.98 for a loss of -54.95 points or -0.22%. The S&P 500 closed at 2,720.13 for a loss of -2.33 points or -0.09%. The Nasdaq Composite closed at 7,382.47 for a loss of -15.82 points or -0.21%. The VIX Volatility Index was lower at 13.34 for a loss of -0.04 points or -0.60%. Read more...
US Market Indexes Mixed on Friday Dow Jones, S&P 500 and Nasdaq Composite report gains for the week
U.S. market indexes were mixed on Friday. The Dow Jones Industrial Average closed at 24,831.17 for a gain of 91.64 points or 0.37%. The S&P 500 closed at 2,727.72 for a gain of 4.65 points or 0.17%. The Nasdaq Composite closed at 7,402.88 for a loss of -2.09 points or -0.03%. The VIX Volatility Index was lower at 12.71 for a loss of -0.52 points or -3.93%. Read more...
Vanguard Health Care Reduces Abbott, Bristol-Myers Positions Fund's largest sales of the 1st quarter
The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks in the first quarter. Read more...
US Market Indexes Close Higher on Monday Dow Jones closes at 24,573.04
U.S. market indexes were higher on Monday. The Dow Jones Industrial Average closed at 24,573.04 for a gain of 212.90 points or 0.87%. The S&P 500 closed at 2,677.84 for a gain of 21.54 points or 0.81%. The Nasdaq Composite closed at 7,156.28 for a gain of 49.63 points or 0.70%. The VIX Volatility Index was lower at 16.42 for a loss of -0.99 points or -5.69%. Read more...
US Stocks Edge Higher on Monday Main indexes up more than 0.5%
U.S. stock market traded higher in Monday pre-market trading after missiles attacked Syria’s chemical weapons on Saturday. Read more...
US Market Indexes Close Higher on Monday Dow Jones closes at 23,979.10
U.S. market indexes were higher on Monday. The Dow Jones Industrial Average closed at 23,979.10 for a gain of 46.34 points or 0.19%. The S&P 500 closed at 2,613.16 for a gain of 8.69 points or 0.33%. The Nasdaq Composite closed at 6,950.34 for a gain of 35.23 points or 0.51%. The VIX Volatility Index was higher at 21.71 for a gain of 0.22 points or 1.02%. Read more...
Charles Brandes Boosts Stake in Avadel Pharmaceuticals Guru sees value in Irish pharmaceutical company
After establishing an 8.72% stake in Avadel Pharmaceuticals PLC (NASDAQ:AVDL) in the fourth quarter of 2017, Charles Brandes (Trades, Portfolio), chairman of Brandes Investment, further expanded his position on March 29. Read more...
4 Stocks Move Monday Monsanto, GM, Therapix Biosciences and Merck rise
Monsanto Co. (NYSE:MON) shares surged on a Wall Street Journal report that the U.S. Justice Department approved the pending $66 billion acquisition by Bayer (BAYRY) after the company agreed to sell additional assets to secure government antitrust approval. Read more...
» More Articles for MRK

Ratios

vs
industry
vs
history
PE Ratio 101.96
MRK's PE Ratio is ranked lower than
83% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. MRK: 101.96 )
Ranked among companies with meaningful PE Ratio only.
MRK' s PE Ratio Range Over the Past 10 Years
Min: 6.33  Med: 23.86 Max: 138.33
Current: 101.96
6.33
138.33
Forward PE Ratio 14.04
MRK's Forward PE Ratio is ranked higher than
76% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. MRK: 14.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 101.96
MRK's PE Ratio without NRI is ranked lower than
83% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. MRK: 101.96 )
Ranked among companies with meaningful PE Ratio without NRI only.
MRK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.33  Med: 23.86 Max: 138.33
Current: 101.96
6.33
138.33
PB Ratio 4.74
MRK's PB Ratio is ranked lower than
64% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. MRK: 4.74 )
Ranked among companies with meaningful PB Ratio only.
MRK' s PB Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.27 Max: 7.25
Current: 4.74
1.72
7.25
PS Ratio 3.95
MRK's PS Ratio is ranked lower than
56% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. MRK: 3.95 )
Ranked among companies with meaningful PS Ratio only.
MRK' s PS Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.38 Max: 5.48
Current: 3.95
2.01
5.48
Price-to-Free-Cash-Flow 30.48
MRK's Price-to-Free-Cash-Flow is ranked lower than
58% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. MRK: 30.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MRK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.88  Med: 16.79 Max: 88.07
Current: 30.48
7.88
88.07
Price-to-Operating-Cash-Flow 22.14
MRK's Price-to-Operating-Cash-Flow is ranked lower than
60% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. MRK: 22.14 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MRK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.68  Med: 14.39 Max: 35.61
Current: 22.14
6.68
35.61
EV-to-EBIT 26.51
MRK's EV-to-EBIT is ranked lower than
58% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. MRK: 26.51 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 18.7 Max: 52.5
Current: 26.51
4.9
52.5
EV-to-EBITDA 15.70
MRK's EV-to-EBITDA is ranked higher than
61% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. MRK: 15.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 9.75 Max: 22.6
Current: 15.7
4.2
22.6
EV-to-Revenue 4.29
MRK's EV-to-Revenue is ranked lower than
58% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. MRK: 4.29 )
Ranked among companies with meaningful EV-to-Revenue only.
MRK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 3.75 Max: 5.5
Current: 4.29
1.9
5.5
Shiller PE Ratio 24.80
MRK's Shiller PE Ratio is ranked higher than
74% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. MRK: 24.80 )
Ranked among companies with meaningful Shiller PE Ratio only.
MRK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.24  Med: 17.92 Max: 30.63
Current: 24.8
8.24
30.63
Current Ratio 1.42
MRK's Current Ratio is ranked lower than
80% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. MRK: 1.42 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.5 Max: 3.7
Current: 1.42
0.97
3.7
Quick Ratio 1.10
MRK's Quick Ratio is ranked lower than
75% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. MRK: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.18 Max: 3.44
Current: 1.1
0.69
3.44
Days Inventory 148.29
MRK's Days Inventory is ranked lower than
65% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. MRK: 148.29 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 125.52  Med: 134.25 Max: 205.16
Current: 148.29
125.52
205.16
Days Sales Outstanding 64.93
MRK's Days Sales Outstanding is ranked higher than
62% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. MRK: 64.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 59.74 Max: 87.87
Current: 64.93
44.5
87.87
Days Payable 89.16
MRK's Days Payable is ranked higher than
60% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. MRK: 89.16 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 38.91  Med: 53.05 Max: 90.81
Current: 89.16
38.91
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.22
MRK's Dividend Yield % is ranked higher than
84% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. MRK: 3.22 )
Ranked among companies with meaningful Dividend Yield % only.
MRK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.51  Med: 3.58 Max: 6.68
Current: 3.22
2.51
6.68
Dividend Payout Ratio 3.28
MRK's Dividend Payout Ratio is ranked lower than
97% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. MRK: 3.28 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MRK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 1 Max: 5.43
Current: 3.28
0.27
5.43
3-Year Dividend Growth Rate 2.20
MRK's 3-Year Dividend Growth Rate is ranked lower than
62% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. MRK: 2.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MRK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.4 Max: 20
Current: 2.2
0
20
Forward Dividend Yield % 3.24
MRK's Forward Dividend Yield % is ranked higher than
81% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. MRK: 3.24 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.61
MRK's 5-Year Yield-on-Cost % is ranked higher than
78% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. MRK: 3.61 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MRK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.81  Med: 4.01 Max: 7.48
Current: 3.61
2.81
7.48
3-Year Average Share Buyback Ratio 1.70
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. MRK: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.9  Med: 1.1 Max: 2.8
Current: 1.7
-12.9
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 85.70
MRK's Price-to-Tangible-Book is ranked lower than
99% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. MRK: 85.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MRK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.19  Med: 11.11 Max: 3112.5
Current: 85.7
3.19
3112.5
Price-to-Intrinsic-Value-Projected-FCF 1.57
MRK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. MRK: 1.57 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MRK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.51 Max: 3.48
Current: 1.57
0.75
3.48
Price-to-Median-PS-Value 1.17
MRK's Price-to-Median-PS-Value is ranked lower than
53% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. MRK: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.19 Max: 2.11
Current: 1.17
0.63
2.11
Price-to-Graham-Number 19.64
MRK's Price-to-Graham-Number is ranked lower than
97% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. MRK: 19.64 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MRK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 3.31 Max: 31.92
Current: 19.64
1.09
31.92
Earnings Yield (Greenblatt) % 3.78
MRK's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. MRK: 3.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.35 Max: 20.6
Current: 3.78
1.9
20.6
Forward Rate of Return (Yacktman) % -1.21
MRK's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. MRK: -1.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MRK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -6  Med: 8.6 Max: 27
Current: -1.21
-6
27

More Statistics

Revenue (TTM) (Mil) $40,725.00
EPS (TTM) $ 0.58
Beta1.10
Volatility20.66%
52-Week Range $52.83 - 66.41
Shares Outstanding (Mil)2,690.30

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 42,040 44,096 45,672
EBIT (Mil $) 12,585 14,067 15,922
EBITDA (Mil $) 15,301 16,460 17,393
EPS ($) 4.22 4.60 5.05
EPS without NRI ($) 4.22 4.60 5.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.42%
Dividends per Share ($) 1.95 2.03 2.01

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK